- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: GSK2857916.
Displaying page 1 of 1.
EudraCT Number: 2017-004810-25 | Sponsor Protocol Number: 205678 | Start Date*: 2018-07-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or Mo... | |||||||||||||
Medical condition: Relapsed/Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001138-32 | Sponsor Protocol Number: 208887 | Start Date*: 2020-09-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study GSK2857916 as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refra... | |||||||||||||
Medical condition: Relapsed/Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) SE (Ongoing) NL (Ongoing) ES (Temporarily Halted) NO (Ongoing) GR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004689-93 | Sponsor Protocol Number: 207497 | Start Date*: 2019-04-29 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lena... | |||||||||||||
Medical condition: Relapsed / Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002125-15 | Sponsor Protocol Number: GEM-BELMA | Start Date*: 2021-08-17 | |||||||||||
Sponsor Name:Fundación Pethema | |||||||||||||
Full Title: An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, refractory to lenalidomide | |||||||||||||
Medical condition: myeloma multiple | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002515-34 | Sponsor Protocol Number: CMG012022 | Start Date*: 2023-03-28 | |||||||||||
Sponsor Name:Czech Myeloma Group | |||||||||||||
Full Title: Phase 2 study of belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma | |||||||||||||
Medical condition: The study will enroll adult participants with RRMM who have been previously treated with at least 1 prior line of therapy, and who have documented disease progression during, or after, their most r... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003047-30 | Sponsor Protocol Number: 209664 | Start Date*: 2020-02-14 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone i... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004151-16 | Sponsor Protocol Number: 209628 | Start Date*: 2021-11-22 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participa... | |||||||||||||
Medical condition: Multiple myeloma = cancer of blood cells in the bone marrow | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) PL (Ongoing) IT (Ongoing) IE (Trial now transitioned) GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003993-29 | Sponsor Protocol Number: 207503 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with th... | |||||||||||||
Medical condition: Relapsed/Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Ongoing) ES (Ongoing) NL (Ongoing) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005826-27 | Sponsor Protocol Number: EAE-2020/MM0107 | Start Date*: 2021-01-26 | |||||||||||
Sponsor Name:Hellenic Society of Hematology (EAE) | |||||||||||||
Full Title: A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Lenalidomide and Dexamethasone in patients w... | |||||||||||||
Medical condition: newly diagnosed multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004354-21 | Sponsor Protocol Number: 207499 | Start Date*: 2020-08-12 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus... | |||||||||||||
Medical condition: Relapsed/Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) FR (Ongoing) PL (Ongoing) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006792-42 | Sponsor Protocol Number: EAE120 | Start Date*: 2022-03-09 | |||||||||||
Sponsor Name:Hellenic Society of Hematology (EAE) | |||||||||||||
Full Title: A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Daratumumab, Lenalidomide and Dexamethasone ... | |||||||||||||
Medical condition: newly diagnosed multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004001-32 | Sponsor Protocol Number: EMN27 | Start Date*: 2021-01-29 | |||||||||||
Sponsor Name: European Myeloma Network – EMN | |||||||||||||
Full Title: A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | |||||||||||||
Medical condition: relapsed or refractory AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) GR (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001413-37 | Sponsor Protocol Number: BELI(E)VE-Trial | Start Date*: 2023-04-24 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) The BELI(E)VE-Trial | |||||||||||||
Medical condition: relapsed and refractory t(11;14) Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004252-38 | Sponsor Protocol Number: 207495 | Start Date*: 2020-04-14 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants wit... | |||||||||||||
Medical condition: Relapsed/Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Ongoing) FR (Ongoing) ES (Ongoing) BE (Ongoing) HU (Ongoing) GR (Ongoing) PL (Ongoing) BG (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001941-19 | Sponsor Protocol Number: EAE127 | Start Date*: 2022-10-26 | |||||||||||
Sponsor Name:Hellenic Society of Hematology (EAE) | |||||||||||||
Full Title: A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Daratumumab, Pomalidomide and Dexamethasone ... | |||||||||||||
Medical condition: Relapsed/refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001942-39 | Sponsor Protocol Number: EAE128 | Start Date*: 2022-10-24 | |||||||||||
Sponsor Name:Hellenic Society of Hematology (EAE) | |||||||||||||
Full Title: A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat... | |||||||||||||
Medical condition: Newly diagnosed patients with multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001442-38 | Sponsor Protocol Number: 64407564MMY3008 | Start Date*: 2022-11-03 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma who have Received at least 4 Prior Therapies Including an Immunomodulatory Dr... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.